Altered expression of HLA class I antigens in breast cancer: Association with prognosis

Citation
I. Gudmundsdottir et al., Altered expression of HLA class I antigens in breast cancer: Association with prognosis, INT J CANC, 89(6), 2000, pp. 500-505
Citations number
37
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF CANCER
ISSN journal
00207136 → ACNP
Volume
89
Issue
6
Year of publication
2000
Pages
500 - 505
Database
ISI
SICI code
0020-7136(20001120)89:6<500:AEOHCI>2.0.ZU;2-3
Abstract
Loss of surface expression of class I major histocompatibility antigens is commonly observed in malignant tumors and has been considered one of the me chanisms for escape from cytotoxic T cells. However, natural killer cells k ill cells lacking HLA class I antigens, In the present study, we characteri zed by immunohistochemistry the HLA class I expression of breast carcinomas from 187 patients with TNM stages I and II, diagnosed 1981-1984, using bet a (2)-microglobulin as a marker and evaluated the effect on survival with a follow-up of up to 14 years. The largest group (48%) consisted of HLA clas s I-negative tumors (less than or equal to 10% of cells stained), mixed exp ression (> 10% and < 80% of cells stained) was seen in 36% and only 15% wer e classified as HLA class I-positive (greater than or equal to 80% cells st ained). No associations could be established with various clinicopathologic al parameters, such as tumor size, presence of lymph node metastases, histo logical grade, expression of hormone receptors, S phase and p53 mutations. There was no effect on recurrence-free survival in the whole group; but amo ng node-negative patients (n = 86), those who had tumors with mixed HLA cla ss I expression had a significantly higher probability of disease recurrenc e (OR = 3.42, p 0.014) than patients with either HLA class I-positive or -n egative tumors, particularly after more than 5 years. In node-positive pati ents who received adjuvant therapy, this phenotype was not associated with disease recurrence. Int. J. Cancer (Pred. Oncol,) 89:500-505, 2000, (C) 200 0 Wiley-Liss, Inc.